Aim: Non-bioartificial liver has been applied to clinic for quite a long time, but the reported efficacy has been very different. The aim of this study was to compare the efficacy and safety of hemoperfusion adsorption, plasma exchange and plasma exchange plus hemoperfusion adsorption in treatment of severe viral hepatitis.
Methods: Seventy-five patients with severe viral hepatitis were treated with hemoperfusion adsorption therapy (24 cases), plasma exchange therapy (17 cases) and plasma exchange plus hemoperfusion adsorption therapy (34 cases). The data of liver function, renal function, blood routine test, prothrombin time (PT) and prothrombin activity (PTa) pre- and post-therapy were analyzed.
Results: Clinical symptoms of patients improved after treatment. The levels of aminotransferase, total bilirubin, direct bilirubin decreased significantly after 3 therapies (P<0.05 or P<0.01). PT, the level of total serum protein decreased significantly and PTa increased significantly after plasma exchange therapy and plasma exchange plus hemoperfusion adsorption therapy (P<0.05 or P<0.01). The side effects were few and mild in all patients.
Conclusion: Three therapies were effective in the treatment of severe viral hepatitis. Plasma exchange therapy and plasma exchange plus hemoperfusion adsorption therapy are better than hemoperfusion adsorption therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656365 | PMC |
| http://dx.doi.org/10.3748/wjg.v10.i8.1218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of Trends and Influencing Factors of Cytokine-Adsorbing Therapies: A Nationwide Ecological Study in Japan.
Cureus
November 2024
Department of Emergency and Critical Care Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, JPN.
Background: Cytokine-adsorption therapy has garnered attention as a potential treatment for conditions such as sepsis, although supporting evidence remains limited. Consequently, its utilization is expected to vary significantly across regions. To date, no ecological studies have investigated this regional heterogeneity.
View Article and Find Full Text PDFHemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A State-Of-The-Art Review.
Blood Purif
November 2024
Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China.
Article Synopsis
- Hemoperfusion using the HA330/HA380 cartridge has become popular in ICUs over the last decade for treating critical illnesses by removing inflammatory substances from the blood.
- While numerous studies indicate its potential benefits in reducing inflammation and organ failure, there is still no comprehensive assessment of its safety and effectiveness in critical care.
- This paper aims to review the HA330/HA380 hemoperfusion technique, summarize recent clinical findings across various conditions, and highlight drug clearance capabilities to address safety issues.
Regenerated carboxymethyl cellulose beads for selective removal of low-density lipoprotein from whole blood.
Carbohydr Polym
January 2025
Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, PR China. Electronic address:
Low-density lipoprotein (LDL) plays a crucial role in the development of cardiovascular disease. Lowering the level of LDL is an effective therapeutic strategy for treating cardiovascular disease. Here, we developed a facile and robust method to prepare carboxymethyl cellulose beads (CMCBs) for selectively adsorbing LDL.
View Article and Find Full Text PDFHemoperfusion with CytoSorb in Pediatric Patients: A Monocentric Case Series.
J Clin Med
November 2024
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Pro- and anti-inflammatory cytokines help regulate the inflammatory response. A cytokine storm is a dysregulated cytokine response associated with sepsis and other conditions that result in a hyper-inflammatory state. Extracorporeal cytokine adsorption has the potential to restore a balanced inflammatory response.
View Article and Find Full Text PDFThe COSMOS Registry of CytoSorb Hemoadsorption Therapy in Critically Ill Patients: Protocol for an International, Prospective Registry.
JMIR Res Protoc
November 2024
Intensive Care Department, Vall d'Hebron University Hospital, Shock, Organ Dysfunction and Resuscitation Research Group (SODIR), Barcelona, Spain.
Background: Extracorporeal blood purification with CytoSorb has been increasingly used as an adjunctive therapy in several hyperinflammatory critical care conditions, as well as to remove elevated levels of myoglobin or bilirubin in patients with rhabdomyolysis or liver failure. Despite the increasing worldwide use of hemoadsorption, data from large international multicenter studies are still lacking.
Objective: The COSMOS (CytoSorb Treatment Of Critically Ill Patients) registry is a company-sponsored registry by CytoSorbents Corporation and CytoSorbents Medical Inc.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!